Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. Issue 3 (10th March 2022)
- Record Type:
- Journal Article
- Title:
- Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. Issue 3 (10th March 2022)
- Main Title:
- Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial
- Authors:
- Agustí, Alvar
De Stefano, Gaston
Levi, Alberto
Muñoz, Xavier
Romero-Mesones, Christian
Sibila, Oriol
Lopez-Giraldo, Alejandra
Plaza Moral, Vicente
Curto, Elena
Echazarreta, Andrés L.
Márquez, Silvana E.
Pascual-Guàrdia, Sergi
Santos, Salud
Marin, Alicia
Valdés, Luis
Saldarini, Fernando
Salgado, Clara
Casanovas, Georgina
Varea, Sara
Ríos, José
Faner, Rosa - Abstract:
- SARS-CoV-2 vaccines have been extremely effective in reducing the incidence of severe coronavirus disease 2019 (COVID-19) [1, 2], but effective and safe treatments for acute infection are still limited [3, 4]. An uncontrolled pulmonary inflammatory response to SARS-CoV-2 is considered a key pathogenic mechanism of COVID-19 progression [5], so systemic dexamethasone is recommended in severe cases [4, 6]. On the other hand, in very mild patients at home, inhaled corticosteroids (ICS) may prevent disease progression [7–10]. Whether ICS can also prevent disease progression in patients hospitalised because of COVID-19 has not been explored previously. Accordingly, we designed an investigator-initiated, open-label, randomised clinical trial (RCT) to explore the efficacy of adding inhaled budesonide to usual care to prevent disease progression in patients hospitalised because of COVID-19 pneumonia. We also carefully monitored the safety of this intervention since there are concerns about the use of systemic corticosteroids in other viral (influenza) lung infections [11]. The addition of inhaled budesonide to usual care is safe and may reduce the risk of disease progression in patients hospitalised because of COVID-19 pneumonia https://bit.ly/3tEQo3p
- Is Part Of:
- European respiratory journal. Volume 59:Issue 3(2022)
- Journal:
- European respiratory journal
- Issue:
- Volume 59:Issue 3(2022)
- Issue Display:
- Volume 59, Issue 3 (2022)
- Year:
- 2022
- Volume:
- 59
- Issue:
- 3
- Issue Sort Value:
- 2022-0059-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-03-10
- Subjects:
- Respiratory organs -- Diseases -- Periodicals
Respiration -- Periodicals
616.2 - Journal URLs:
- http://erj.ersjournals.com ↗
http://www.ersnet.org ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=mrj ↗
http://www.ingenta.com/journals/browse/ers/erj?mode=direct ↗ - DOI:
- 10.1183/13993003.03036-2021 ↗
- Languages:
- English
- ISSNs:
- 0903-1936
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24757.xml